What does apalutamide prescribing information include?
Apalutamide prescribing information (PI) is the FDA-approved document that summarizes how clinicians should use the medicine, including approved indications, dosing, how to take it, key safety warnings, and monitoring guidance. It also lists contraindications, common and serious adverse reactions, dose modifications for side effects, and information patients need to know.
What is the approved use (indication) for apalutamide?
Apalutamide is prescribed for men with non-metastatic, castration-resistant prostate cancer (nmCRPC) and for metastatic castration-sensitive prostate cancer (mCSPC), as reflected in its FDA-approved labeling.
What is the usual apalutamide dose and schedule?
The standard prescribing dose is 240 mg by mouth once daily (as multiple tablets), with dose timing and administration detailed in the PI (including what to do if a dose is missed).
How should apalutamide be taken (with or without food)?
The PI describes the administration instructions for apalutamide, including whether it can be taken with or without food and how tablets should be swallowed.
What major warnings and precautions are listed?
Apalutamide labeling includes boxed or prominent warnings and other key precautions covering:
- Falls and fractures
- Seizures
- Cardiovascular effects
- Drug interactions (particularly CYP-related interactions)
- Neurologic effects and other important risks
The PI also specifies monitoring and dose-change steps for relevant adverse events.
What side effects are most commonly reported?
The prescribing information lists adverse reactions, including common events seen in clinical use (such as fatigue, falls, rash, hypertension, and weight loss) and more serious events that require prompt management and possible treatment interruption or discontinuation.
What dose adjustments are recommended if side effects happen?
The PI includes dose modification guidance for toxicities (including neurologic events, skin reactions, and other serious adverse reactions). It also explains when to hold treatment and when to resume or discontinue based on severity.
Can apalutamide interact with other medicines?
Yes. The prescribing information includes clinically important drug–drug interaction information, especially around effects on drug-metabolizing enzymes and transporters. Clinicians are instructed to review the patient’s current medication list for interaction risk and to adjust therapy accordingly.
What should prescribers know about pregnancy or fertility risk?
The prescribing information includes reproductive safety information relevant to the patient population, including embryo-fetal risk language where applicable and counseling points for health-care providers.
Where can I find the official apalutamide prescribing information?
For the most current FDA labeling text and required safety information, use the prescribing information document linked by the manufacturer or the FDA label database. A patent and exclusivity reference for apalutamide is also available via DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “apalutamide”).
Sources
- DrugPatentWatch.com